Epizyme, Inc. (NASDAQ:EPZM) will be issuing its quarterly earnings data before the market opens on Friday, August 4th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.07. Epizyme had a negative return on equity of 55.41% and a negative net margin of 1,376.33%. On average, analysts expect Epizyme to post $-2.42 EPS for the current fiscal year and $-2.39 EPS for the next fiscal year.

Shares of Epizyme, Inc. (EPZM) traded up 2.89% on Thursday, reaching $12.45. The company’s stock had a trading volume of 378,961 shares. The firm’s 50 day moving average is $13.86 and its 200-day moving average is $14.31. Epizyme, Inc. has a 52-week low of $7.02 and a 52-week high of $18.50. The stock’s market cap is $726.56 million.

EPZM has been the subject of several recent research reports. Cann reiterated a “buy” rating and issued a $26.00 price target on shares of Epizyme in a research report on Tuesday, April 25th. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Tuesday, May 16th. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research report on Friday, May 19th. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research report on Wednesday, June 7th. Finally, Oppenheimer Holdings, Inc. set a $26.00 price target on Epizyme and gave the company a “buy” rating in a research report on Monday, June 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $23.75.

In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $16.11, for a total value of $241,650.00. Following the completion of the sale, the insider now owns 22,228 shares of the company’s stock, valued at approximately $358,093.08. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew E. Singer sold 3,024 shares of the business’s stock in a transaction dated Friday, June 30th. The shares were sold at an average price of $15.50, for a total value of $46,872.00. Following the completion of the sale, the chief financial officer now directly owns 40,529 shares of the company’s stock, valued at approximately $628,199.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,524 shares of company stock valued at $746,797. Corporate insiders own 25.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Epizyme, Inc. (EPZM) Set to Announce Quarterly Earnings on Friday” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/03/epizyme-inc-epzm-set-to-announce-quarterly-earnings-on-friday.html.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Earnings History for Epizyme (NASDAQ:EPZM)

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.